Literature DB >> 18657727

HIV infection of the central nervous system: clinical features and neuropathogenesis.

Lysa Boissé1, M John Gill, Christopher Power.   

Abstract

Almost 65 million people worldwide have been infected with HIV since it was first identified in the early 1980s. Neurologic disorders associated with HIV type 1 affect between 40% and 70% of infected individuals. The most significant of these disorders include HIV-associated neurocognitive disorder, which comprises HIV-associated dementia, mild neurocognitive disorder, and asymptomatic neurocognitive impairment. Despite the availability of combination antiretroviral therapy, HIV-related central nervous system disorders continue to represent a substantial personal, economic, and societal burden. This review summarizes the clinical manifestations, diagnosis, treatment, and pathogenesis of the primary HIV-associated central nervous system disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18657727     DOI: 10.1016/j.ncl.2008.04.002

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  72 in total

Review 1.  New insights for FOXO and cell-fate decision in HIV infection and HIV associated neurocognitive disorder.

Authors:  Min Cui; Yunlong Huang; Yong Zhao; Jialin Zheng
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

2.  Socioeconomic Status and Neuropsychological Functioning: Associations in an Ethnically Diverse HIV+ Cohort.

Authors:  Alyssa Arentoft; Desiree Byrd; Jennifer Monzones; Kelly Coulehan; Armando Fuentes; Ana Rosario; Caitlin Miranda; Susan Morgello; Monica Rivera Mindt
Journal:  Clin Neuropsychol       Date:  2015-04-14       Impact factor: 3.535

3.  Effects of vitamin A deficiency and opioids on parvalbumin + interneurons in the hippocampus of the HIV-1 transgenic rat.

Authors:  Ming Guo; Joseph Bryant; Shireen Sultana; Odell Jones; Walter Royal
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

4.  Preferential sensitivity of human dopaminergic neurons to gp120-induced oxidative damage.

Authors:  Shuxian Hu; Wen S Sheng; James R Lokensgard; Phillip K Peterson; R Bryan Rock
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

Review 5.  Neuropathogenesis of HIV-1-associated neurocognitive disorders: a possible involvement of D-serine.

Authors:  Jianxun Xia; Huangui Xiong
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2013-09-10

6.  Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.

Authors:  Pawel Ciborowski
Journal:  Biomark Med       Date:  2009-12       Impact factor: 2.851

Review 7.  Targeting anti-HIV drugs to the CNS.

Authors:  Kavitha S Rao; Anuja Ghorpade; Vinod Labhasetwar
Journal:  Expert Opin Drug Deliv       Date:  2009-08       Impact factor: 6.648

8.  Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection.

Authors:  Gretja Schnell; Richard W Price; Ronald Swanstrom; Serena Spudich
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

9.  The Impact of Depressive Symptoms on Neuropsychological Performance Tests in HIV-Infected Individuals: A Study of the Hawaii Aging with HIV Cohort.

Authors:  Sheri M Shimizu; Dominic C Chow; Victor Valcour; Kamal Masaki; Beau Nakamoto; Kalpana J Kallianpur; Cecilia Shikuma
Journal:  World J AIDS       Date:  2011-12-01

10.  Suppression of HIV-1 Infectivity by Human Glioma Cells.

Authors:  Sheikh Ariful Hoque; Atsushi Tanaka; Salequl Islam; Gias Uddin Ahsan; Atsushi Jinno-Oue; Hiroo Hoshino
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-07       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.